Immuron secured exclusive U.S. distribution rights for PROIBS with Calmino group AB, targeting a digestive and gut health supplement market valued at $4.16 billion. The agreement expands Immuron’s digestive health portfolio and gives investors a defined U.S. commercial opportunity for a medical device already launched in Australia.

Key Highlights

  • Immuron executed an exclusive U.S. distribution agreement for PROIBS with Calmino group AB.
  • A usability study of 1,003 PROIBS users found the product helpful for 94% of participants.
  • The company said 91% of users experienced an improvement in daily life, while 98% would recommend PROIBS to someone else.

Immuron Ltd (NASDAQ: IMRN) executed an exclusive U.S. distribution agreement for PROIBS with Calmino group AB, targeting a subset of the U.S. digestive and gut health supplement market, which is valued overall at $4.16 billion.

PROIBS Agreement Covers U.S. Distribution Immuron

executed the agreement with Calmino group AB on September 4, 2026. It contains AVH200®, a substance derived from Aloe barbadensis Mill. Whose gel-forming components support the intestinal mucosal barrier. The product is suitable for long-term use, and the company said it has an excellent safety profile with no known interactions with other medications. The device is European certified.

User Study Supports Digestive Health Positioning Calmino’s usability study covered 1,003 users.

PROIBS was considered helpful by 94% of participants, while 91% said it improved their daily life and 98% said they would recommend it to someone else. Immuron said the agreement forms part of a strategy to build a portfolio of innovative digestive health products in the United States. The company launched PROIBS in Australia during FY26 and described the U.S. agreement as an opportunity to extend that portfolio with a product it characterizes as science-driven and physician- and dietitian-recommended.